Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch
Tip Ranks·- Wolfe Research analyst Rudy Li maintained a buy rating on Stoke Therapeutics with a target price of 40.00 dollars. - The rating is supported by the successful completion of the Phase 3 EMPEROR trial for zorevunersen and a clear regulatory timeline pointing to a 2028 commercial launch. - A robust cash reserve of approximately 420,000,000 dollars further secures the company's path through upcoming clinical and regulatory milestones.